A3P

Log in

Nosopharm raises EUR 2,4 million to develop a new antibiotic

The young Nosopharm pharmaceutical company said Tuesday it has raised € 2,4 million to help it develop a new class of antibiotics.

Read more...

Commercial green light to the US for treatment of Sanofi against severe eczema

The French pharmaceutical giant Sanofi and its US partner Regeneron announced Tuesday the approval of the US Dupixent (dupilumab), a first biomedicine indicated for the treatment of severe eczema in which Sanofi has high hopes.

Read more...

Measles outbreak in Europe: WHO calls for vaccination

A measles epidemic has hit Europe, from France to Ukraine, due to insufficient vaccination, warned Tuesday the World Health Organization.

Read more...

Roche: American green light to a treatment against multiple sclerosis

The Swiss pharmaceutical group Roche said on Wednesday that the US drug agency approved its new treatment against multiple sclerosis, Ocrevus, marking a breakthrough in the treatment of disease.

Read more...

A test for the rapid detection of tuberculosis developed

US researchers have developed a blood test that should significantly accelerate the diagnosis and treatment of tuberculosis, an infection that nearly two million deaths per year worldwide.

Read more...

a3p-100pxhaut logo

 fren

Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )


  group    administrators A3P
    
& Project Managers

letter   newsletter A3P